佩尼希克利丁化通过抑制热致死来缓解肺缺血-再输液损伤

相关实验视频

Updated: Jun 27, 2025

Author Spotlight: Insights into the Effect of Ischemia Reperfusion on Lung Transplantation
06:45

Author Spotlight: Insights into the Effect of Ischemia Reperfusion on Lung Transplantation

Published on: April 12, 2024

1.4K

Rongfang Liu1,2, Xuguang Zhang3, Jing Yan4

  • 1Department of Anesthesiology, the Second Hospital of Hebei Medical University, NO. 215 of HePing West Road, Xinhua District Shijiazhuang, 050000, Shijiazhuang, China.

BMC pulmonary medicine
|April 26, 2024
PubMed
概括

基化 (PHC) 通过抑制细胞死亡途径 - - 热致死 - - 减少大鼠模型中的肺损伤. 这种治疗减轻了氧化应激和炎症,改善了缺血-再输液后的肺功能.

关键词:
炎症反应是一种炎症反应.左侧的山丘紧.肺缺血-再输液损伤的肺缺血是什么氧化应激是一种氧化应激.佩尼希克利丁化.热灭菌的发生.

更多相关视频

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes07:37

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes

Published on: October 28, 2021

2.9K
Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices13:32

Videomorphometric Analysis of Hypoxic Pulmonary Vasoconstriction of Intra-pulmonary Arteries Using Murine Precision Cut Lung Slices

Published on: January 14, 2014

10.8K

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
148